Eutylone

Eutylone is expressly listed at entry 161 of the current official police consolidation of the non-medical catalogue under the Chinese chemical name 1-[3,4-(亚甲二氧基)苯基]-2-乙氨基-1-丁酮 and the English chemical name 1-(3,4-Methylenedioxyphenyl)-2-(ethylamino)butan-1-one, with CAS number 802855-66-9. The three-agency catalogue announcement took effect on publication on 21 July 2025 and repealed the former Supplementary Catalogue. A further three-agency announcement added 16 substances effective 1 July 2026; the Shenzhen Public Security Bureau consolidation current through that date retains Eutylone as entry 161. Regulation Article 4 permits non-medical controlled substances to be used only for experimental research conducted under the Regulation and prohibits their production, operation, use, storage, and transport. Public Security Administration Punishments Law Article 84, effective 1 January 2026, imposes detention and possible fines for illegal possession of a small quantity of other drugs. Criminal Law Article 348 criminalizes illegal possession of larger quantities of other drugs, while Article 357 defines drugs to include other state-controlled addictive narcotic drugs and psychotropic substances. Eutylone is therefore prohibited for ordinary possession and use, subject to the Regulation's narrow experimental-research authorization.

Eutylon (N-Ethylnorbutylon, bk-EBDB) is expressly and individually listed in Anlage II with the chemical name 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)butan-1-on. The Thirty-third Regulation amending narcotics law inserted this entry and took effect on 21 December 2022, the day after its publication. Under § 1 Abs. 1, substances in Anlagen I to III are Betäubungsmittel. Anlage II describes marketable but non-prescribable narcotics; § 3 requires authorization for covered dealings including acquisition, and § 29 Abs. 1 Satz 1 Nr. 3 criminalizes possession without written authorization to acquire. The applicable canonical status is therefore prohibited despite the limited possibility of authorized commerce.

Eutylone is expressly listed as EUTILON, also known as bk-EBDB, at item 172 of Indonesia’s current Group I narcotics schedule. Regulation No. 15 of 2025 took effect upon promulgation on 28 November 2025 and revoked Regulation No. 7 of 2025. The regulation defines Group I narcotics as substances usable only for scientific-development purposes, not in therapy, and with a very high potential to cause dependence. The Ministry of Health’s official JDIH record marks Regulation No. 15 of 2025 as in force, supporting the canonical status prohibited subject to the regulation’s limited scientific-use framework.

Japan expressly designates Eutylone and its salts as narcotics. The Ministry of Health, Labour and Welfare's 27 July 2022 notice identifies the newly designated substance by the chemical name 2-ethylamino-1-(3,4-methylenedioxyphenyl)butan-1-one and by the common names Eutylone and bk-EBDB. The notice states that Cabinet Order No. 255 of 2022 was promulgated on 27 July 2022 and entered into force 30 days later, on 26 August 2022. The current e-Gov text of Cabinet Order No. 238 of 1990 continues to list the same chemical structure and its salts in Article 1, item 16, under the provision designating listed substances as narcotics. Article 28 of the current Narcotics and Psychotropics Control Act prohibits possession by persons outside the licensed and specifically excepted categories. The applicable canonical status is therefore prohibited.

N-ethylbutylon (eutylon) is expressly and individually listed in Opiumwet Lijst I with the chemical description 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)butaan-1-on. Staatsblad 2023, 289 inserted that entry and took effect on 12 September 2023, the day after its 11 September 2023 publication. The current consolidated Opiumwet, valid from 9 July 2026 onward, retains the exact entry. Article 2 prohibits importing or exporting, cultivating, preparing, modifying, processing, selling, delivering, supplying, transporting, possessing, and manufacturing a Lijst I substance. Article 2a(2)(j) excludes substances governed by Articles 2 and 3 from the separate Lijst IA group prohibition, so eutylone's operative classification is its individual Lijst I designation rather than analog or group coverage.

Eutylone is expressly inscribed in Schedule 7. Government Notice 2685 made the inscription effective on 28 October 2022, and SAHPRA's 1 August 2025 consolidation retained it. SAHPRA now identifies a 6 July 2026 consolidation as the latest version and Government Notice 7446 of 8 May 2026 as the latest amending notice. Notice 7446 amends only Schedule 4 by inserting yohimbine when intended for veterinary use; it neither omits Eutylone nor changes Schedule 7. Section 22A(9)(a)(i) prohibits acquiring, using, possessing, manufacturing or supplying a Schedule 7 substance without a Director-General permit. Permits may be issued subject to conditions for specified patient treatment or prevention and for education, analysis or research.

Spain expressly controls eutylone (eutilona), including its possible stereochemical variants, racemates, and salts, in List II of Annex 1 to Royal Decree 2829/1977. The official Council of State record identifies eutilona as 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one, establishing that the Spanish name covers eutylone. Order SND/136/2023 took effect on 19 February 2023, the day after its publication. The BOE consolidated decree, whose latest published update is 21 April 2026, retains eutilona as List II item 58. List II is a controlled authorization-and-prescription regime rather than the blanket prohibition that Article 2 applies to List I: manufacture and commercial handling require authorization and records, import or export requires prior authorization, and pharmacy dispensing requires a medical prescription. The 2023 order stated that no medicines containing the newly listed substances were then authorized in Spain.

WHO identifies eutylone (bk-EBDB) as the synthetic cathinone 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one. Turkish Penal Code Article 188 prohibits unauthorized manufacture, import, export, domestic sale, supply, transport, storage, purchase, acceptance, and possession of narcotic or stimulant drugs in the trafficking context. Law No. 7445 Article 17 expressly places synthetic cathinones and their derivatives within Article 188(4)(a), where the penalty for Article 188 offenses is increased by half.

Brazil expressly names Eutilona in List F2 and identifies it as 1-(1,3-benzodioxol-5-il)-2-(etilamino)butan-1-ona, establishing exact coverage of eutylone rather than coverage only through a structural class. Annex I places List F2 within the Lists of Substances of Proscribed Use in Brazil. RDC No. 784/2023 inserted Eutilona into List F2 by name and took effect on 6 April 2023. ANVISA's current controlled-substances page identifies RDC No. 1,036/2026 as the version in force, and that resolution's consolidated Annex I continues to list EUTILONA with the same chemical identity in List F2. The substance therefore maps to prohibited under the canonical vocabulary.

Eutylon is expressly listed by its exact chemical identity, 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one, as item 181 of List B. List B substances may be used only for medical or scientific purposes, and receipt and possession are permitted only in the circumstances enumerated by the order, including lawful prescription and licensed institutional or commercial activity. The order took effect on 29 March 2026 and repealed BEK nr. 2446 of 12 December 2021. The Danish Medicines Agency's live control-list page, updated 31 March 2026, identifies BEK nr. 405 as the governing order and its consolidated list independently reproduces Eutylon as B181.

Eutylone is expressly listed in Schedule II of the 1971 Convention under its exact chemical identity, and the scheduling decision became effective on 23 November 2022. Mexico promulgated the Convention in the Diario Oficial de la Federación. The Convention defines a psychotropic substance by inclusion in Schedules I-IV, makes later scheduling decisions fully effective for each party after 180 days absent an exceptional notice, limits Schedule II use and possession to medical and scientific purposes, and requires licensing for manufacture, trade and distribution. Mexico's Ley General de Salud subjects acts involving psychotropics to applicable treaties and requires Secretaría de Salud authorization. Código Penal Federal article 193 also treats psychotropics determined by binding treaties as narcotics, but its next paragraph limits conduct punishable under that chapter to substances covered by specified Ley General de Salud provisions; this entry therefore does not assert a general domestic criminal-possession ban. Eutylone is not named in current article 245, and the official searches recorded here located neither a substance-specific article-246 determination nor an affirmative Mexican medicine authorization. The supported classification is consequently restricted_other for treaty and health-authorization controls, not prescription_only or prohibited.

The Ministry of Public Health notification published in the Royal Gazette on 22 May 2023 added Eutylone (ยูทิโลน) as item 84 in the Category I narcotics schedule, identifying it by the chemical name 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one. Clause 2 made the notification effective on the day after publication, 23 May 2023. The Thailand FDA's consolidated table updated 15 September 2025 continues to list Eutylone under Category I. The FDA's current ministerial-notice index, which includes publications through 31 July 2026, shows the 2025 Category I amendment No. 5 as in force and no later Category I naming notification. Under the FDA's summary of the Narcotics Code, unauthorized manufacture, import, export, sale, or possession of a Category I narcotic is punishable, as are possession and consumption, supporting the prohibited canonical status.